Sidley Represents Sino Biopharmaceutical in its US$7 Billion Licensing Agreement With Boehringer Ingelheim

Sidley represented Sino Biopharmaceutical Limited in an option and license agreement with Boehringer Ingelheim covering six preclinical oncology programs involving antibody-drug conjugates (ADCs) and T-cell engagers (TCEs). Under the agreement, Sino Biopharmaceutical will receive US$358 million in upfront and near-term payments and is eligible for up to US$7 billion in additional milestone payments, plus royalties on future product sales. Sino Biopharmaceutical will lead early development through global Phase I clinical trials, after which Boehringer Ingelheim may exercise options to obtain exclusive development and commercialization rights. The transaction marks the second oncology collaboration between the companies.

More information about the transaction is available here.

The Sidley team was led by Lila Hope (Technology and Life Sciences Transactions) and included Ruchun Ji (M&A); Jennifer Raab, Jean Qiu, Collin Marshall, and Yuhan Wu (Technology and Life Sciences Transactions); and Chen Yang (Food, Drug and Medical Device).